(HCAT) Health Catalyst - Ratings and Ratios
Ignite Platform Analytics Applications Professional Services Data Integration
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 64.5% |
| Value at Risk 5%th | 99.9% |
| Relative Tail Risk | -5.84% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.43 |
| Alpha | -89.36 |
| CAGR/Max DD | -0.47 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.477 |
| Beta | 1.329 |
| Beta Downside | 1.252 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.25% |
| Mean DD | 48.57% |
| Median DD | 50.00% |
Description: HCAT Health Catalyst January 01, 2026
Health Catalyst, Inc. (NASDAQ: HCAT) is a U.S.-based provider of data- and analytics-focused technology and professional services for health-care organizations. The firm operates two primary segments: a Technology segment built around its Ignite data-and-analytics platform, and a Professional Services segment that delivers implementation, data-governance, and population-health consulting.
Ignite serves as a single, cloud-native environment that aggregates disparate clinical, financial, and operational data sources, enabling customers to run a suite of pre-built analytics applications. These applications target clinical improvement, revenue-cycle optimization, ambulatory operations, quality-measure reporting, and registry management, all powered by the same underlying data model.
The company’s client roster spans academic medical centers, integrated delivery networks, community hospitals, large physician groups, ACOs, health-information exchanges, insurers, life-science firms, and health-tech vendors-essentially any risk-bearing entity that must turn fragmented health data into actionable insight.
According to its FY 2023 Form 10-K, Health Catalyst generated $726 million in revenue, a 19 % year-over-year increase, with subscription-based recurring revenue now comprising roughly 68 % of total sales. Gross margins have stabilized near 78 %, reflecting the high-margin nature of its software-as-a-service model, while cash flow from operations exceeded $150 million, supporting continued R&D and strategic acquisitions.
Key sector drivers include the accelerating shift to value-based care, which pressures providers to demonstrate cost-efficiency and quality outcomes, and federal interoperability mandates (e.g., the 21st Century Cures Act) that compel health systems to consolidate siloed data. Moreover, the overall health-care data-analytics market is projected to grow at a CAGR of ~12 % through 2028, expanding the addressable opportunity for platforms that can deliver real-time, actionable insights.
If you’re interested in a deeper, data-driven valuation of HCAT, a quick look at ValueRay’s analyst toolkit can help you model scenario-based outcomes without the guesswork.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-107.6m TTM) > 0 and > 6% of Revenue (6% = 19.0m TTM) |
| FCFTA -0.04 (>2.0%) and ΔFCFTA -1.97pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 24.51% (prev 44.24%; Δ -19.73pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.02 (>3.0%) and CFO -12.7m > Net Income -107.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (70.4m) change vs 12m ago 16.44% (target <= -2.0% for YES) |
| Gross Margin 46.50% (prev 45.22%; Δ 1.28pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 45.15% (prev 37.15%; Δ 7.99pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -3.10 (EBITDA TTM -32.7m / Interest Expense TTM 26.0m) >= 6 (WARN >= 3) |
Altman Z'' -5.61
| (A) 0.13 = (Total Current Assets 165.4m - Total Current Liabilities 87.9m) / Total Assets 587.1m |
| (B) -2.17 = Retained Earnings (Balance) -1.27b / Total Assets 587.1m |
| warn (B) unusual magnitude: -2.17 — check mapping/units |
| (C) -0.12 = EBIT TTM -80.6m / Avg Total Assets 700.1m |
| (D) 1.30 = Book Value of Equity 331.9m / Total Liabilities 255.2m |
| Total Rating: -5.61 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 31.98
| 1. Piotroski 2.50pt |
| 2. FCF Yield -9.42% |
| 3. FCF Margin -7.21% |
| 4. Debt/Equity 0.52 |
| 5. Debt/Ebitda -4.03 |
| 6. ROIC - WACC (= -19.93)% |
| 7. RoE -30.28% |
| 8. Rev. Trend 92.56% |
| 9. EPS Trend 1.62% |
What is the price of HCAT shares?
Over the past week, the price has changed by -9.52%, over one month by -15.24%, over three months by -22.97% and over the past year by -69.19%.
Is HCAT a buy, sell or hold?
- Strong Buy: 7
- Buy: 2
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the HCAT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.9 | 72.8% |
| Analysts Target Price | 3.9 | 72.8% |
| ValueRay Target Price | 1.3 | -44.3% |
HCAT Fundamental Data Overview January 04, 2026
P/E Forward = 11.3766
P/S = 0.5102
P/B = 0.5093
Beta = 1.729
Revenue TTM = 316.1m USD
EBIT TTM = -80.6m USD
EBITDA TTM = -32.7m USD
Long Term Debt = 151.5m USD (from longTermDebt, last quarter)
Short Term Debt = 5.48m USD (from shortTermDebt, last quarter)
Debt = 172.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 131.8m USD (from netDebt column, last quarter)
Enterprise Value = 241.8m USD (161.3m + Debt 172.1m - CCE 91.5m)
Interest Coverage Ratio = -3.10 (Ebit TTM -80.6m / Interest Expense TTM 26.0m)
FCF Yield = -9.42% (FCF TTM -22.8m / Enterprise Value 241.8m)
FCF Margin = -7.21% (FCF TTM -22.8m / Revenue TTM 316.1m)
Net Margin = -34.05% (Net Income TTM -107.6m / Revenue TTM 316.1m)
Gross Margin = 46.50% ((Revenue TTM 316.1m - Cost of Revenue TTM 169.1m) / Revenue TTM)
Gross Margin QoQ = 49.55% (prev 47.37%)
Tobins Q-Ratio = 0.41 (Enterprise Value 241.8m / Total Assets 587.1m)
Interest Expense / Debt = 3.27% (Interest Expense 5.63m / Debt 172.1m)
Taxrate = -0.18% (negative due to tax credits) (41.0k / -22.2m)
NOPAT = -80.8m (EBIT -80.6m * (1 - -0.18%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 1.88 (Total Current Assets 165.4m / Total Current Liabilities 87.9m)
Debt / Equity = 0.52 (Debt 172.1m / totalStockholderEquity, last quarter 331.9m)
Debt / EBITDA = -4.03 (negative EBITDA) (Net Debt 131.8m / EBITDA -32.7m)
Debt / FCF = -5.78 (negative FCF - burning cash) (Net Debt 131.8m / FCF TTM -22.8m)
Total Stockholder Equity = 355.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.33% (Net Income -107.6m / Total Assets 587.1m)
RoE = -30.28% (Net Income TTM -107.6m / Total Stockholder Equity 355.4m)
RoCE = -15.91% (EBIT -80.6m / Capital Employed (Equity 355.4m + L.T.Debt 151.5m))
RoIC = -12.96% (negative operating profit) (NOPAT -80.8m / Invested Capital 623.2m)
WACC = 6.97% (E(161.3m)/V(333.4m) * Re(10.91%) + D(172.1m)/V(333.4m) * Rd(3.27%) * (1-Tc(-0.00)))
Discount Rate = 10.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.41%
Fair Price DCF = unknown (Cash Flow -22.8m)
EPS Correlation: 1.62 | EPS CAGR: 13.68% | SUE: -0.01 | # QB: 0
Revenue Correlation: 92.56 | Revenue CAGR: 4.50% | SUE: 2.12 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.08 | Chg30d=-0.018 | Revisions Net=-3 | Analysts=6
EPS next Year (2026-12-31): EPS=0.35 | Chg30d=-0.068 | Revisions Net=-6 | Growth EPS=+72.9% | Growth Revenue=-2.6%
Additional Sources for HCAT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle